Skip to content

Olaparib

Generic Medicine With 13 Brands Available In Bangladesh. Read What It Is For And How It Is Taken, Then Compare The Brands By Strength, Maker And Price.

Generic Guide

About Olaparib

What This Generic Is For, How It Is Taken, And What To Watch For.

Indications

Ovarian cancer Breast Cancer: Olaparib is indicated as monotherapy for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who have previously been treated with chemotherapy ... Read more Breast Cancer: Olaparib is indicated as monotherapy for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who have previously been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have progressed on or be considered inappropriate for endocrine therapy. Germline BRCA mutation must be confirmed before Olaparib treatment is initiated. Ovarian Cancer: Olaparib is indicated as monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed (PSR) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to platinumbased chemotherapy.

Dosage And Administration

There is a risk of medication errors between Olaparib tablets and Olaparib capsules. In order to minimize this risk, check the bottle labels to ensure that the drug being prepared and dispensed is Olaparib tablets and not Olaparib capsules. Prescribers should specify the formulation and dosage of Olaparib on each prescription. The recommended total daily dose of Olaparib tablets is 600 mg, taken as two 150 mg tablets twice daily. The 100 mg tablet is available for dose reduction. For treatment of ovarian cancer: Patients should start treatment with Olaparib no later than 8 weeks after completion of their final dose of the platinum-containing regimen. Patients should have recovered from prior hematologic toxicities prior to starting Olaparib therapy (hemoglobin, platelet, and neutrophil levels should be ≤ CTCAE grade 1). It is recommended that Olaparib treatment be continued until progression of the underlying disease or unacceptable toxicity. Olaparib should not be given in combination with other anti cancer therapy. Grapefruit or other similar fruit juices that are known to inhibit CYP3A should not be consumed while taking Olaparib.

Side Effects

The most common serious adverse reaction reported was anemia (2.4% olaparib vs 2.2% chemotherapy). The following serious ADRs were reported in one patient each: dermatitis allergic, neutrophil count decreased and platelet count decreased. The proportion of patients who permanently discontinued Olaparib due to adverse events was 4.9% in the Olaparib arm compared with 7.7% in the chemotherapy arm. Anemia and platelet count decrease were the only adverse reactions leading to discontinuation of Olaparib in more than one patient.

Precautions And Warnings

Myelodysplastic Syndrome/Acute Myeloid Leukemia (MDS/AML): occurred in patients exposed to Olaparib, and the majority of reports were fatal. Monitor patients for hematological toxicity at baseline and monthly thereafter. Discontinue if MDS/AML is confirmed. Pneumonitis: occurred in patients exposed to Olaparib, and some cases were fatal. Interrupt treatment if pneumonitis is suspected. Discontinue if pneumonitis is confirmed. Embryo-Fetal Toxicity: Olaparib can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception

Pregnancy And Lactation

Pregnancy: Olaparib can cause fetal harm when administered to a pregnant woman based on its mechanism of action and findings in animals. Olaparib wasteratogenic and caused embryo-fetal toxicity in rats at exposures below those in patients receiving the recommended human dose of 400 mg twice daily. If this drug is used during pregnancy, or if a patient becomes pregnant while taking this drug, apprise the patient of the potential hazard to the fetus and the potential risk for loss of the pregnancy. Nursing Mothers: It is not known whether olaparib is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from olaparib, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250

Clinical Details

BestinMeds shares medicine information to help you compare. It does not replace advice from your doctor or pharmacist.

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250

Available Brand Names: 13

Sorted By
Capsule

Inpoza 50 mg

Generic: Olaparib

800.00Taka / Unit

View Medicine
Tablet

Inpoza 150 mg

Generic: Olaparib

2000.00Taka / Unit

View Medicine
Tablet

Juparib 100 mg

Generic: Olaparib

1508.00Taka / Unit

View Medicine
Tablet

Juparib 150 mg

Generic: Olaparib

2320.00Taka / Unit

View Medicine
Tablet

Olacent 150 mg

Generic: Olaparib

350.00Taka / Unit

View Medicine
Tablet

Olacent 100 mg

Generic: Olaparib

250.00Taka / Unit

View Medicine
Tablet

Olanib 150 mg

Generic: Olaparib

833.33Taka / Unit

View Medicine
Tablet

Olapar 150 mg

Generic: Olaparib

1700.00Taka / Unit

View Medicine
Tablet

Olapar 100 mg

Generic: Olaparib

1150.00Taka / Unit

View Medicine
Capsule

Olarigen 50 mg

Generic: Olaparib

535.71Taka / Unit

View Medicine
Tablet

Olarigen 150 mg

Generic: Olaparib

833.33Taka / Unit

View Medicine
Tablet

Parib 150 mg

Generic: Olaparib

Price Not Available

View Medicine
Capsule

Parib 50 mg

Generic: Olaparib

Price Not Available

View Medicine

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250